PROM1 and cancer: To characterize and target CD133-positive cancer stem cells, the patient-derived de-identified melanoma cell line, BAK parental (BAKP), harboring a refractory NRAS driver mutation and expressing low basal CD133 levels, was transduced with a Tet activator (rtTA3, Addgene) and a Tet-on vector expressing CD133 (TRE3G-CD133, VectorBuilder).